Pharvaris (NASDAQ:PHVS) Raised to Hold at Wall Street Zen

Pharvaris (NASDAQ:PHVS) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

PHVS has been the subject of several other research reports. Citizens Jmp decreased their price target on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. UBS Group set a $74.00 price target on shares of Pharvaris in a research note on Wednesday, May 13th. Royal Bank Of Canada decreased their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Wolfe Research assumed coverage on shares of Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $49.18.

Pharvaris Price Performance

Shares of NASDAQ PHVS opened at $31.09 on Friday. The company has a market cap of $2.03 billion, a P/E ratio of -9.78 and a beta of -2.35. Pharvaris has a 1 year low of $15.99 and a 1 year high of $33.33. The firm has a 50-day simple moving average of $29.24 and a two-hundred day simple moving average of $27.30.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, equities research analysts expect that Pharvaris will post -3.22 EPS for the current year.

Insider Activity at Pharvaris

In related news, Director Robert Glassman sold 10,000 shares of Pharvaris stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $29.82, for a total transaction of $298,200.00. Following the transaction, the director directly owned 10,500 shares of the company’s stock, valued at $313,110. This trade represents a 48.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Peng Lu sold 15,000 shares of Pharvaris stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the transaction, the insider directly owned 66,083 shares in the company, valued at approximately $1,998,349.92. The trade was a 18.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 209,948 shares of company stock valued at $6,268,141 over the last quarter. 11.84% of the stock is owned by insiders.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently bought and sold shares of PHVS. Wellington Management Group LLP purchased a new position in Pharvaris during the third quarter valued at approximately $43,282,000. Paradigm Biocapital Advisors LP grew its holdings in Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after purchasing an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Pharvaris in the third quarter worth $15,613,000. Commodore Capital LP grew its holdings in Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares during the last quarter. Finally, General Atlantic L.P. grew its holdings in Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after purchasing an additional 500,000 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.